Keryx Biopharmaceuticals Announces Appointment Of Daniel W. Olmstead As Vice President, Payer Access

NEW YORK, Jan. 21, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced the appointment of Daniel W. Olmstead to the newly created position of Vice President, Payer Access. In this role, Mr. Olmstead will lead the Company's strategic global market access, managed care and reimbursement initiatives.

Mr. Olmstead brings more than 25 years of healthcare experience, with the majority of this time spent in a variety of managed market roles, including reimbursement access, contracting, and product launch planning and execution. Prior to joining the Company, Mr. Olmstead was a National Account Director for Walgreen Co. (NYSE:WAG), where he represented all Walgreens business units with Express Scripts, its largest volume retail client. Prior to joining Walgreens in 2012, Mr. Olmstead spent more than 7 years with Genzyme/Sanofi, ultimately rising to Senior Director, Corporate Accounts. During his tenure at Genzyme/Sanofi, Mr. Olmstead served in roles of increasing responsibility within the Renal Division, including coverage of key national and regional health plans, managed markets product launch planning, and playing an integral role in establishing Renal pricing and contracting strategies for Renagel ®/Renvela ®, Hectorol ® and other products. Mr. Olmstead received his Bachelor's degree from the University of Michigan, Ann Arbor.

Daniel P. Regan, a member of Keryx's Board of Directors, and formerly Global General Manager, Senior Vice President of the Renal Franchise at Genzyme/Sanofi, commented, "Having worked with Dan at Genzyme/Sanofi for several years, I believe that he will be a tremendous asset to the Company at this critical juncture. Dan is a consummate professional and I believe that his breadth of experience, particularly in the Renal space, will help the Company develop and implement sound pricing, market access and reimbursement approaches globally to achieve commercial success."

If you liked this article you might like

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

5 Breakout Stocks Under $10 Set to Soar

Today's Perilous Reversal Stock: Keryx Biopharmaceuticals (KERX)